Company initiates process to explore a broad range of strategic alternatives to maximize shareholder valuePITTSBURGH, Nov. 13, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: POAI), a science driven company ...
Our lead product candidate, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in an ongoing Phase ...
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and ...
Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive ...